• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮冠状动脉介入治疗后慢性阻塞性肺疾病患者的主要不良心脏事件和死亡率:一项系统评价和荟萃分析

Major adverse cardiac events and mortality in chronic obstructive pulmonary disease following percutaneous coronary intervention: a systematic review and meta-analysis.

作者信息

Bundhun Pravesh Kumar, Gupta Chakshu, Xu Guang Ma

机构信息

Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530027, People's Republic of China.

Guangxi Medical University, Nanning, Guangxi, 530027, People's Republic of China.

出版信息

BMC Cardiovasc Disord. 2017 Jul 17;17(1):191. doi: 10.1186/s12872-017-0622-2.

DOI:10.1186/s12872-017-0622-2
PMID:28716059
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5514536/
Abstract

BACKGROUND

We aimed to systematically compare Major Adverse Cardiac Events (MACEs) and mortality following Percutaneous Coronary Intervention (PCI) in patients with and without Chronic Obstructive Pulmonary Diseases (COPD) through a meta-analysis.

METHODS

Electronic databases (Cochrane library, EMBASE and Medline/PubMed) were searched for English publications comparing in-hospital and long-term MACEs and mortality following PCI in patients with a past medical history of COPD. Statistical analysis was carried out by Revman 5.3 whereby Odds Ratio (OR) and 95% Confidence Intervals (CI) were considered the relevant parameters.

RESULTS

A total number of 72,969 patients were included (7518 patients with COPD and 65,451 patients without COPD). Results of this analysis showed that in-hospital MACEs were significantly higher in the COPD group with OR: 1.40, 95% CI: 1.19-1.65; P = 0.0001, I = 0%. Long-term MACEs were still significantly higher in the COPD group with OR: 1.58, 95% CI: 1.38-1.81; P = 0.00001, I = 29%. Similarly, in-hospital and long-term mortality were significantly higher in patients with COPD, with OR: 2.25, 95% CI: 1.78-2.85; P = 0.00001, I = 0% and OR: 2.22, 95% CI: 1.33-3.71; P = 0.002, I = 97% respectively. However, the result for the long-term death was highly heterogeneous.

CONCLUSION

Since in-hospital and long-term MACEs and mortality were significantly higher following PCI in patients with versus without COPD, COPD should be considered a risk factor for the development of adverse clinical outcomes following PCI. However, the result for the long-term mortality was highly heterogeneous warranting further analysis.

摘要

背景

我们旨在通过荟萃分析系统比较经皮冠状动脉介入治疗(PCI)后有和没有慢性阻塞性肺疾病(COPD)的患者的主要不良心脏事件(MACE)和死亡率。

方法

检索电子数据库(Cochrane图书馆、EMBASE和Medline/PubMed),查找比较有COPD病史患者PCI后住院期间和长期MACE及死亡率的英文出版物。使用Revman 5.3进行统计分析,将优势比(OR)和95%置信区间(CI)视为相关参数。

结果

共纳入72969例患者(7518例COPD患者和65451例非COPD患者)。该分析结果显示,COPD组住院期间MACE显著更高,OR:1.40,95%CI:1.19 - 1.65;P = 0.0001,I = 0%。COPD组长期MACE仍显著更高,OR:1.58,95%CI:1.38 - 1.81;P = 0.00001,I = 29%。同样,COPD患者的住院期间和长期死亡率显著更高,OR分别为:2.25,95%CI:1.78 - 2.85;P = 0.00001,I = 0%和OR:2.22,95%CI:1.33 - 3.71;P = 0.002,I = 97%。然而,长期死亡结果的异质性很高。

结论

由于有COPD的患者PCI后住院期间和长期的MACE及死亡率显著高于无COPD的患者,COPD应被视为PCI后不良临床结局发生的危险因素。然而,长期死亡率结果的异质性很高,需要进一步分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/d52f25266fb7/12872_2017_622_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/1f50a1347c52/12872_2017_622_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/1ed591540df8/12872_2017_622_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/c159773b85f4/12872_2017_622_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/92f14b567ff1/12872_2017_622_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/b045a958dc7c/12872_2017_622_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/e213c51fcbf0/12872_2017_622_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/505218fb3b73/12872_2017_622_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/0cf9c932117c/12872_2017_622_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/fb7b51fdf055/12872_2017_622_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/2065459b48c8/12872_2017_622_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/d52f25266fb7/12872_2017_622_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/1f50a1347c52/12872_2017_622_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/1ed591540df8/12872_2017_622_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/c159773b85f4/12872_2017_622_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/92f14b567ff1/12872_2017_622_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/b045a958dc7c/12872_2017_622_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/e213c51fcbf0/12872_2017_622_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/505218fb3b73/12872_2017_622_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/0cf9c932117c/12872_2017_622_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/fb7b51fdf055/12872_2017_622_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/2065459b48c8/12872_2017_622_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8b7/5514536/d52f25266fb7/12872_2017_622_Fig11_HTML.jpg

相似文献

1
Major adverse cardiac events and mortality in chronic obstructive pulmonary disease following percutaneous coronary intervention: a systematic review and meta-analysis.经皮冠状动脉介入治疗后慢性阻塞性肺疾病患者的主要不良心脏事件和死亡率:一项系统评价和荟萃分析
BMC Cardiovasc Disord. 2017 Jul 17;17(1):191. doi: 10.1186/s12872-017-0622-2.
2
Does infection with human immunodeficiency virus have any impact on the cardiovascular outcomes following percutaneous coronary intervention?: a systematic review and meta-analysis.感染人类免疫缺陷病毒对经皮冠状动脉介入治疗后的心血管结局有何影响?一项系统评价和荟萃分析。
BMC Cardiovasc Disord. 2017 Jul 17;17(1):190. doi: 10.1186/s12872-017-0624-0.
3
Outcomes of percutaneous coronary intervention in patients with coronary chronic total occlusions with versus without type 2 diabetes mellitus: A systematic review and meta-analysis.伴有与不伴有2型糖尿病的冠状动脉慢性完全闭塞患者经皮冠状动脉介入治疗的结果:一项系统评价和荟萃分析
Medicine (Baltimore). 2017 Nov;96(45):e8499. doi: 10.1097/MD.0000000000008499.
4
Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012 - 2016).冠状动脉血管成形术后,氯吡格雷与质子泵抑制剂联合使用是否仍与不良心血管结局增加相关?:对近期发表的研究(2012 - 2016年)的系统评价和荟萃分析
BMC Cardiovasc Disord. 2017 Jan 5;17(1):3. doi: 10.1186/s12872-016-0453-6.
5
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者自我管理干预措施(包括针对病情加重的行动计划)与常规护理的比较。
Cochrane Database Syst Rev. 2017 Aug 4;8(8):CD011682. doi: 10.1002/14651858.CD011682.pub2.
6
Same Day Discharge versus Overnight Stay in the Hospital following Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.稳定性冠状动脉疾病患者经皮冠状动脉介入治疗后当日出院与住院过夜的比较:一项随机对照试验的系统评价和荟萃分析
PLoS One. 2017 Jan 9;12(1):e0169807. doi: 10.1371/journal.pone.0169807. eCollection 2017.
7
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病自我管理的计算机和移动技术干预措施。
Cochrane Database Syst Rev. 2017 May 23;5(5):CD011425. doi: 10.1002/14651858.CD011425.pub2.
8
Worse clinical outcomes following percutaneous coronary intervention with a high SYNTAX score: A systematic review and meta-analysis.高SYNTAX评分患者经皮冠状动脉介入治疗后临床结局更差:一项系统评价和荟萃分析。
Medicine (Baltimore). 2017 Jun;96(24):e7140. doi: 10.1097/MD.0000000000007140.
9
Self-management interventions for people with chronic obstructive pulmonary disease.针对慢性阻塞性肺疾病患者的自我管理干预措施。
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.

引用本文的文献

1
Association between chronic obstructive pulmonary disease and in-hospital mortality after percutaneous coronary intervention: a retrospective cohort study in Germany.慢性阻塞性肺疾病与经皮冠状动脉介入治疗后院内死亡率的关联:德国的一项回顾性队列研究
Sci Rep. 2024 Mar 13;14(1):6044. doi: 10.1038/s41598-024-56255-3.
2
Editorial: Chronic inflammation, oxidative stress and lipoprotein metabolism in cardio-pulmonary continuum.社论:心肺连续体中的慢性炎症、氧化应激与脂蛋白代谢
Front Cardiovasc Med. 2022 Dec 23;9:1055370. doi: 10.3389/fcvm.2022.1055370. eCollection 2022.
3
Impact of Spirometrically Confirmed Chronic Obstructive Pulmonary Disease on Arterial Stiffness and Surfactant Protein D After Percutaneous Coronary Intervention. The CATEPOC Study.

本文引用的文献

1
Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.慢性阻塞性肺疾病对心房颤动预后的影响:欧洲观察性研究计划心房颤动试点调查(EORP-AF)总登记处的报告
Am Heart J. 2016 Nov;181:83-91. doi: 10.1016/j.ahj.2016.08.011. Epub 2016 Aug 27.
2
Subclinical cardiovascular disease in patients with chronic obstructive pulmonary disease: a systematic review.慢性阻塞性肺疾病患者的亚临床心血管疾病:系统评价。
QJM. 2017 Jun 1;110(6):341-349. doi: 10.1093/qjmed/hcw135.
3
Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease.
肺量计确诊慢性阻塞性肺疾病对经皮冠状动脉介入治疗后动脉僵硬度和表面活性蛋白 D 的影响。CATEPOC 研究。
Int J Chron Obstruct Pulmon Dis. 2022 Oct 14;17:2577-2587. doi: 10.2147/COPD.S373853. eCollection 2022.
4
Effects of chronic obstructive pulmonary disease on long-term prognosis of patients with coronary heart disease post-percutaneous coronary intervention.慢性阻塞性肺疾病对冠心病患者经皮冠状动脉介入治疗后长期预后的影响。
J Geriatr Cardiol. 2022 Jun 28;19(6):428-434. doi: 10.11909/j.issn.1671-5411.2022.06.005.
5
Long-Term Outcomes for Chinese COPD Patients After PCI: A Propensity Score Matched, Double-Cohort Study.中国慢性阻塞性肺疾病患者经皮冠状动脉介入治疗后的长期结局:一项倾向评分匹配的双队列研究。
Front Cardiovasc Med. 2022 Jun 9;9:827635. doi: 10.3389/fcvm.2022.827635. eCollection 2022.
6
Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study.慢性阻塞性肺疾病对复杂冠状动脉疾病经皮冠状动脉介入治疗和旁路手术后 10 年死亡率的影响:来自 SYNTAX 扩展生存研究的见解。
Clin Res Cardiol. 2021 Jul;110(7):1083-1095. doi: 10.1007/s00392-021-01833-y. Epub 2021 Mar 12.
7
In-hospital outcomes of percutaneous mitral valve repair in patients with chronic obstructive pulmonary disease: insights from the national inpatient sample database.慢性阻塞性肺疾病患者经皮二尖瓣修复术的院内转归:来自全国住院患者样本数据库的见解。
Catheter Cardiovasc Interv. 2021 Jan 1;97(1):E104-E112. doi: 10.1002/ccd.28913. Epub 2020 May 6.
8
Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease.慢性阻塞性肺疾病作为心血管疾病关键危险因素的研究进展。
Int J Chron Obstruct Pulmon Dis. 2020 Apr 14;15:755-764. doi: 10.2147/COPD.S238214. eCollection 2020.
概述了在管理同时患有心血管疾病和慢性阻塞性肺疾病的患者时,医生面临的药理学挑战。
Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):205-11. doi: 10.1093/ehjcvp/pvv019. Epub 2015 Apr 6.
4
Association between carotid intima-media thickness and presence of coronary artery disease in chronic obstructive pulmonary disease patients.慢性阻塞性肺疾病患者颈动脉内膜中层厚度与冠状动脉疾病存在情况的关联
Anatol J Cardiol. 2016 Aug;16(8):601-607. doi: 10.5152/AnatolJCardiol.2015.6440. Epub 2015 Nov 25.
5
Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study.经皮冠状动脉介入治疗后慢性阻塞性肺疾病的漏诊与预后:一项前瞻性研究。
Int J Chron Obstruct Pulmon Dis. 2015 Jul 16;10:1353-61. doi: 10.2147/COPD.S84482. eCollection 2015.
6
Prevalence of chronic obstructive pulmonary disease and its association with tobacco smoking and environmental tobacco smoke exposure among rural population.农村人群中慢性阻塞性肺疾病的流行情况及其与吸烟和环境烟草烟雾暴露的关系。
Indian J Public Health. 2014 Jan-Mar;58(1):45-9. doi: 10.4103/0019-557X.128166.
7
Impact of chronic obstructive pulmonary disease on patient with acute myocardial infarction undergoing primary percutaneous coronary intervention.慢性阻塞性肺疾病对行直接经皮冠状动脉介入治疗的急性心肌梗死患者的影响。
Biomed J. 2013 Nov-Dec;36(6):274-81. doi: 10.4103/2319-4170.113373.
8
Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty--a BOLD analysis.慢性阻塞性肺疾病死亡率和患病率:与吸烟和贫困的关系——BOLD 分析。
Thorax. 2014 May;69(5):465-73. doi: 10.1136/thoraxjnl-2013-204460. Epub 2013 Dec 18.
9
Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.慢性阻塞性肺疾病对行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者长期预后的影响。
Chest. 2013 Sep;144(3):750-757. doi: 10.1378/chest.12-2313.
10
Impact of chronic obstructive pulmonary diseases on outcomes and hospital days after percutaneous coronary intervention.慢性阻塞性肺疾病对经皮冠状动脉介入治疗后结局和住院天数的影响。
Angiology. 2013 Aug;64(6):430-4. doi: 10.1177/0003319712458145. Epub 2012 Aug 31.